Authors
Latest:
Dr. Kahl on the Utility of Tafasitamab/Lenalidomide in DLBCLBrad S. Kahl, MD, discusses the utility of tafasitamab combined with lenalidomide in patients with diffuse large B-cell lymphoma who are ineligible for CAR T-cell therapy.
Latest:
CAR T Pioneers Describe Challenges Faced in CancerAdvances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.
Latest:
Liso-Cel Approved for R/R B-Cell Lymphoma by European CommissionThe decision was based on findings from the phase 1 TRANSCEND NHL 001 clinical trial.
Latest:
Nikhil Munshi, MD, on Final Data on Cilta-Cel in Multiple Myeloma From CARTITUDE-1The associate professor from Dana Farber Cancer Center and Harvard Medical School discussed continued efficacy and safety data presented at the 2023 EHA Meeting.
Latest:
Adriana Rossi, MD and Luciano J. Costa, MD, PhD on Earlier CAR T in Multiple MyelomaOncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.
Latest:
CAR T-Cell Therapy for Multiple Myeloma: What Community Oncologists Need to KnowThe emergence of cellular-based therapies represents a major opportunity to improve outcomes in the heavily pretreated and refractory myeloma population.
Latest:
Dr. Deol on the Curative Potential of CAR T-Cell Therapy in ALLAbhinav Deol, MD, discusses the role of CAR T-cell therapy in pediatric patients with acute lymphoblastic leukemia.
Latest:
Dr. Bachier on the Potential Benefits of Liso-Cel in DLBCLCarlos R. Bachier, MD, discusses the investigational CAR T-cell therapy lisocabtagene maraleucel in diffuse large B-cell lymphoma.
Latest:
Dr. Gajra on Adverse Effects Associated With CAR T-Cell Therapy in Hematologic MalignanciesAjeet Gajra, MD, FACP, discusses adverse effects associated with CAR T-cell therapy in hematologic malignancies.
Latest:
Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple MyelomaJesus G. Berdeja, MD, discusses the dosing of the investigational CAR T-cell product JNJ-4528 in patients with relapsed/refractory multiple myeloma.
Latest:
Real-World Axi-Cel Data Show QOL Improvements in LBCLThe first year after treatment yielded statistically significant improvements in overall QOL and symptoms within the first year of treatment for relapsed/refractory large B-cell lymphoma
Latest:
New Project Aims to Increase CAR T Safety, AvailabilityA new project is manufacturing a “purified” version of CAR-T-cells currently used to treat types of lymphoma and leukemia.
Latest:
Dr. Brody on Managing CAR T-Cell Therapy Toxicities in MCLJoshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.
Latest:
Dr. Davids on the Future of CAR T-Cell Therapy in CLLMatthew S. Davids, MD, MMSc, discusses the future of CAR T-cell therapy in chronic lymphocytic leukemia.
Latest:
Dr. Mesa on the Potential Utility of CAR T-Cell Therapy in MPNsRuben A. Mesa, MD, discusses the potential utility of CAR T-cell therapy in myeloproliferative neoplasms.
Latest:
Dr. Abid on Challenges With CAR T-Cell Therapy During the COVID-19 PandemicMuhammad Bilal Abid, MD, MRCP, discusses challenges with CAR-T cell therapy during the coronavirus disease 2019 pandemic.
Latest:
Dr. Kansagra on Updates With CAR T-Cell Therapy in Hematologic CancersAnkit Kansagra, MD, discusses key updates with CAR T-cell therapy in hematologic cancers.
Latest:
CAR T-Cell Research SurgesHundreds of trials are under way, 3 CAR T-cell therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma.
Latest:
Dr. Sauter on Off-The-Shelf Versus Autologous CAR T-Cell Products in Hematologic MalignanciesCraig Sauter, MD, discusses the differences between off-the-shelf and autologous chimeric antigen receptor T-cell products in patients with hematologic malignancies.
Latest:
Expert Highlights Efficacy of KTE-C19 CAR T-Cell Therapy in Non-Hodgkin LymphomaKTE-C19, an investigational CAR T-cell therapy, recently demonstrated positive results for patients with chemorefractory aggressive non-Hodgkin lymphoma.
Latest:
Dr. Chaudhary on Short-Term and Long-Term Future of CAR T-CellsPreet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses the short-term and long-term future of CAR T-cells.
Latest:
Long Term Follow-Up of Axi-Cel in R/R Non-Hodgkin Lymphoma : Sattva S. Neelapu, MDThe professor from The University of Texas MD Anderson Cancer Center discussed long-term follow-up analysis of the phase 2 ZUMA-5 trial.
Latest:
Ide-Cel and Lenalidomide Maintenance in MM Following Suboptimal ASCT ResponseAlfred L. Garfall, MD, MS, discussed data from the phase 2 BMT CTN 1902 trial.
Latest:
Novel Treatments for Multiple Myeloma: C. Ola Landgren, MD, PhDThe inaugural leader of the Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center, University of Miami discussed exciting novel therapeutic approaches in multiple myeloma.
Latest:
CAR T-Cell Therapy Starts to Enter MCL SpaceFrederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.
Latest:
Future of MCL Treatment May Lie in Combinations, CAR T-Cell TherapyRobert Dean, MD, discusses the promise for new therapies in mantle cell lymphoma.
Latest:
Dr. Smith Discusses CAR T Cell Persistence in MyelomaEric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.
